Clinical Trial Update: Bevacizumab Combined With Gefitinib in the Treatment of Advanced NSCLC [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating bevacizumab in combination with gefitinib for advanced non-small cell lung cancer (NSCLC) with progression-free survival as a key condi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Bevacizumab (bevacizumab)
• Gefitinib (Gefitinib)

Snippet

Sponsor: Fudan University | Conditions: PFS | Phase 2 | Status: UNKNOWN